RICTOR/mTORC2 downregulation in BRAFV600E melanoma cells promotes resistance to BRAF/MEK inhibition.

doi:10.1186/s12943-024-02010-1

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

RICTOR/mTORC2 downregulation in BRAFV600E melanoma cells promotes resistance to BRAF/MEK inhibition.

Molecular cancer - 16 May 2024

Ponzone Luca, Audrito Valentina, Landi Claudia, Moiso Enrico, Levra Levron Chiara, Ferrua Sara, Savino Aurora, Vitale Nicoletta, Gasparrini Massimiliano, Avalle Lidia, Vantaggiato Lorenza, Shaba Enxhi, Tassone Beatrice, Saoncella Stefania, Orso Francesca, Viavattene Daniele, Marina Eleonora, Fiorilla Irene, Burrone Giulia, Abili Youssef, Altruda Fiorella, Bini Luca, Deaglio Silvia, Defilippi Paola, Menga Alessio, Poli Valeria, Porporato Paolo Ettore, Provero Paolo, Raffaelli Nadia, Riganti Chiara, Taverna Daniela, Cavallo Federica, Calautti Enzo

Abstract excerpt

BACKGROUND: The main drawback of BRAF/MEK inhibitors (BRAF/MEKi)-based targeted therapy in the management of BRAF-mutated cutaneous metastatic melanoma (MM) is the development of therapeutic resistance. We aimed to assess in this context the role of mTORC2, a signaling complex defined by the presence of the essential RICTOR subunit, regarded as an oncogenic driver in several tumor types, including MM. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Down-Regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to MAP Kinase Kinase Kinases

Share to Mechanistic Target of Rapamycin Complex 2

Share to Melanoma

Share to Proteomics

Share to Proto-Oncogene Proteins B-raf

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 38755661
DOI: 10.1186/s12943-024-02010-1
PMCID: PMC11097536

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RICTOR/mTORC2 downregulation in BRAFV600E melanoma cells promotes resistance to BRAF/MEK inhibition.PMID 38755661Read ↗

NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic TargetsSemantic proximity Read ↗

NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in MelanomaSemantic proximity Read ↗

Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma.Semantic proximity Read ↗

BRAFV600E negatively regulates the AKT pathway in melanoma cell lines.Semantic proximity Read ↗

RICTOR involvement in the PI3K/AKT pathway regulation in melanocytes and melanoma.Semantic proximity Read ↗

TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.Semantic proximity Read ↗

Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells.Semantic proximity Read ↗

Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAFV600 melanoma.Semantic proximity Read ↗

Inhibition of the Rho/MRTF pathway improves the response of BRAF-resistant melanoma to PD1/PDL1 blockadeSemantic proximity Read ↗

Epigenetic suppression of PGC1α (PPARGC1A) causes collateral sensitivity to HMGCR-inhibitors within BRAF-treatment resistant melanomas.Semantic proximity Read ↗

Mechanistic insights into Rho/MRTF inhibition-induced apoptotic events and prevention of drug resistance in melanoma: Implications for the involvement of pirinSemantic proximity Read ↗

Tumors carrying BRAF-mutations over-express NAMPT that is genetically amplified and possesses oncogenic properties.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.